Search results for "Adverse effect"

showing 10 items of 1065 documents

2019

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth. Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray ab…

0301 basic medicinemedicine.medical_specialtybusiness.industrySirolimus therapyLow doseDiscovery and development of mTOR inhibitorsGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicinePrimary outcome030220 oncology & carcinogenesisSirolimusInternal medicinemedicineAsymmetric overgrowthbusinessAdverse effectPathologicalGenetics (clinical)medicine.drugGenetics in Medicine
researchProduct

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

2019

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hype…

0301 basic medicinemedicine.medical_specialtymedicine.drug_class030106 microbiologyCardiovascular risk factorsType 2 diabetesDiseaseTyrosine-kinase inhibitorSettore MED/15 - Malattie Del Sangue03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientAdverse effectPharmacologybusiness.industryPonatinibChronic myeloid leukemiaMyeloid leukemiaGeneral Medicinemedicine.diseaseCardiovascular riskInfectious DiseasesOncologychemistry030220 oncology & carcinogenesisPonatinibbusiness
researchProduct

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

2016

Background: The identification of biomarkers for the estimation of cancer patients’ survival is a crucial problem in modern oncology. Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events. Therefore, the analysis of survival distribution of patients starting from their profile obtained using DMET data may reveal important information to clinicians about possible correlations among drug response, survival rate, and gene variants. Methods: In order to provide support …

0301 basic medicinepharmacogenomicoverall survivalBiomedical EngineeringDME genes; genotyping microarrays; overall survival; pharmacogenomics; progression-free survivalBioengineeringBiologyBioinformaticsBiochemistryArticlelcsh:Biochemistrygenotyping microarray03 medical and health sciencesmedicineOverall survivallcsh:QD415-436Progression-free survivalgenotyping microarraysAdverse effectSurvival rateGeneADMEpharmacogenomicsADME geneCancermedicine.diseaseADME genesgenotyping microarrays; ADME genes; pharmacogenomics; overall survival; progression-free survival030104 developmental biologyPharmacogenomicsprogression-free survivalBiotechnologyMicroarrays (Basel, Switzerland)
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

In Vivo Cardiotoxicity Induced by Sodium Aescinate in Zebrafish Larvae

2016

Sodium aescinate (SA) is a widely-applied triterpene saponin product derived from horse chestnut seeds, possessing vasoactive and organ-protective activities with oral or injection administration in the clinic. To date, no toxicity or adverse events in SA have been reported, by using routine models (in vivo or in vitro), which are insufficient to predict all aspects of its pharmacological and toxicological actions. In this study, taking advantage of transparent zebrafish larvae (Danio rerio), we evaluated cardiovascular toxicity of SA at doses of 1/10 MNLC, 1/3 MNLC, MNLC and LC10 by yolk sac microinjection. The qualitative and quantitative cardiotoxicity in zebrafish was assessed at 48 h p…

0301 basic medicinesodium aescinateEmbryo NonmammalianHeart malformationDrug Evaluation PreclinicalPharmaceutical Science010501 environmental sciencesPharmacology01 natural sciencesAnalytical ChemistryHeart RateDrug DiscoveryToxicity Tests ChronicZebrafishYolk SacbiologyCommunicationHeartLC10medicine.anatomical_structureChemistry (miscellaneous)LarvaToxicityMolecular MedicineHeart Defects CongenitalMicroinjectionscardiotoxicityHemorrhagelarvaelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryIn vivoHeart ratemedicineMNLCAnimalsPhysical and Theoretical ChemistryYolk sacAdverse effect0105 earth and related environmental sciencesCardiotoxicityDose-Response Relationship DrugOrganic ChemistryThrombosisSaponinsbiology.organism_classificationzebrafishTriterpenes030104 developmental biologyMolecules
researchProduct

FRI0265 Selexipag in Raynaud's Phenomenon Secondary To Systemic Sclerosis: A Randomised, Placebo-Controlled, Phase II Study

2016

Background Raynaud9s phenomenon (RP) occurs in >95% of patients (pts) with systemic sclerosis (SSc) and contributes to digital ischaemia that may lead to digital ulcers (DUs) and gangrene.1,2 Empirical treatment of SSc-associated RP includes oral vasodilators, particularly calcium channel blockers and intermittent intravenous prostacyclin analogues.3,4 However, there is a need to identify oral therapies that are more efficacious than those currently available. Objectives To determine the activity of selexipag, an oral, selective, prostacyclin receptor agonist, on RP attack frequency in pts with SSc. Methods The study comprised a placebo single-blind run-in phase of 2–4-weeks followed by an …

030203 arthritis & rheumatologymedicine.medical_specialtyFuture studiesStudy drugbusiness.industryImmunologyPhases of clinical researchCondition scoreSelexipagPlaceboGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundSafety profile0302 clinical medicineRheumatologychemistryInternal medicinemedicineImmunology and Allergy030212 general & internal medicinebusinessAdverse effectAnnals of the Rheumatic Diseases
researchProduct

Local complications associated with labial salivary gland biopsy for diagnosis of Sjögren?s Syndrome : a retrospective cohort study

2019

Background To describe local or systemic complications related to the labial salivary glands biopsy (LSGB) used as diagnostic tool for the diagnosis of Sjogren's Syndrome (SS). Material and methods Clinical databases from a cohort of patients, who underwent LSGB with provisional clinical diagnosis of Sjogren's Syndrome, were retrospectively reviewed. Pain, assessed by registering the intake of analgesic drugs in the first week following the biopsy, and any further relevant clinical information regarding complications after biopsy were recorded. Results 50 patients received LSGB. 10 of them (9 women and 1 man) showed histopathological findings compatible with SS. Ten patient (20%) receiving …

030203 arthritis & rheumatologymedicine.medical_specialtyOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryResearchAnalgesicRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Surgery03 medical and health sciencesLabial salivary gland0302 clinical medicineBiopsy SiteUNESCO::CIENCIAS MÉDICASBiopsyCohortmedicineSjogren sAdverse effectbusinessGeneral Dentistry
researchProduct

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of a…

2017

Lutz E Pillunat,1 Carl Erb,2 Auli Ropo,3 Friedemann Kimmich,4 Norbert Pfeiffer5 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Augenklinik am Wittenbergplatz, Berlin, Germany; 3Santen Europe, Helsinki, Finland; 4eyecons, Pfinztal, 5Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany Background: Efficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany.Objective: To assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setti…

030213 general clinical medicinemedicine.medical_specialtyIntraocular pressureOpen angle glaucomagenetic structuresfixed combinationGlaucomaTimololOcular hypertension03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectOriginal Researchpreservative-free medicationbusiness.industrytafluprostTafluprostClinical Ophthalmologymedicine.diseasetimololeye diseasesOphthalmologyglaucomaTolerability030221 ophthalmology & optometrysense organspreservativesbusinessmedicine.drugClinical Ophthalmology (Auckland, N.Z.)
researchProduct

PERITRAUMATIC FACTORS AND POSTTRAUMATIC SYMPTOMS IN CHILD SEXUAL ABUSE CASES

2017

Health and legal professionals are aware of adverse effects child sexual abuse (CSA) can have on child development as well as the individual differences in severity of psychological outcomes. The objective of this pilot study was to identify possible explanations that could account for the CSA psychological outcome variability and give insights for further research. A sample of 25 Russian speaking girls by the decision of the person directing the proceedings were recognized as CSA victims and were assigned to psychological or complex psychiatric and psychological expert examination. During examination demographical data was collected and several self-report measures regarding peritraumatic …

050103 clinical psychologybusiness.industry05 social sciencesStepwise regression analysisChild developmentPeritraumatic distressPeritraumatic dissociationChild sexual abuseCorrelation analysisMedicine0501 psychology and cognitive sciencesAdverse effectbusiness050104 developmental & child psychologyClinical psychologyVisuomenės sveikata
researchProduct